|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1001 G Street, NW |
Address2 | Suite 425W |
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 9897-12
|
||||||||
|
6. House ID# 308370000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Michael Giuliani |
Date | 5/8/2026 2:14:00 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.8163 - To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program
S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program.
S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes
S.4110 - A bill to revise and extend health workforce programs under title VII of the Public Health Service Act
H.R.7961 - Physicians and the Healthcare Workforce Act
S.4086 - A bill to establish protections for health care providers who raise concerns about the quality of health care services, and for other purposes
S.4039 - Professional Degree Access Restoration Act
H.R.7884 - To amend the Internal Revenue Code of 1986 to provide a tax credit to health care professionals that provide health care services in qualifying facilities, and for other purposes;
S.3908 - SOS: Sustaining Outpatient Services Act
H.R.7686 - To recognize the importance of clinical roles of locum tenens physicians, and for other purposes
H.R.7520 - Efficiency Adjustment Delay Act
S.3762 - Prior Authorization Relief Act
H.R.7118 - Genomic Answers for Childrens Health Act
H.R. 1, the One Big, Beautiful Bill Act
Improving seniors' timely access to care act (S. 1816 / H.R. 3514)
Genomic Data Protection Act
Tariffs
PAMA reform
S 1399, the Health Tech Investment Act
H.R. 3580, the Oversight of Medicare Billing Code Cost Act
S. 1916 - Protect Genetic information after bankruptcy
S 1830 - HHS has no authority to regulate the practice of medicine
LCD legislation
HR2389/S1302 - Resident Physician Shortage Reduction Act
S2333 - Public Health Workforce Loan Repayment Act
S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act
CLIA Waiver
CURES 2.0
To prevent across-the-board direct spending cuts
HR 5392, the Timely Access to Coverage Decisions Act of 2023
Remote digital telepathology
HR 4527 - HEALTH DATA Act
Primary Care and Health Workforce Expansion Act
Gene Therapy
HR 6371 - budget neutrality bill
S. 1546/H.R. 3152 The Patent Eligibility Restoration Act
Cures 2.1
S. 4935, Physician Fee Stabilization Act
Medical Lab Personnel Shortage Relief Act
S. 1380 - SPARC Act
S. 942/H.R. 2028 - REDI Act
H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025
Issues relating to regulation of laboratory diagnostics
CDC Division of Cancer Prevention and Control and cancer registries appropriations
S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act
H.R.5371 - Continuing Appropriations and Extensions Act, 2026
S 2420 / H.R. 4710 - No Surprises Act Enforcement Act
S 2793 - Ensuring Access to Essential Providers Act of 2025
H.R. 5582 / S 2355 - Patients Deserve Price Tags Act
Issues related to public health
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Giuliani |
|
|
|
Darren |
Fenwick |
|
|
|
Michael |
Hurlbut |
|
|
|
Kristin |
McDonald |
|
|
|
Justin |
Fisher |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Senate Amendments to H.R. 7148 - Consolidated Appropriations Act, 2026
FY 2026 Appropriations
Student VISA issues
Price Tags / Transparency Legislation
CDC funding
NIH Funding
Issues relating to surprise medical bills
Advocating for relief from cuts to evaluation and management codes within Medicare
Issues relating to site-neutral payments
Issue relating to artificial intelligence
Issues relating to Medicare coverage pathways
Researching Long Covid
Issues relating to the Clinical Laboratory Fee Schedule
Issues relating to forensic pathologist loan repayment
Funding for the CDC AMD program
Funding for lab test harmonization
Issues surrounding Health Data Privacy
Medicare payment reform
Challenges facing independent medicine
PTAC Reform
Issues relating to the local coverage determination process
Issues relating to GME
Issues relating to laboratory accreditation procedures of IVF centers
Issues relating to site neutral payment reform
Issues relating to Medicaid funding
S. 2761 and H.R. 5269, the RESULTS Act
Issues related to cancer
Issues related to the Medicare Access and CHIP Reauthorization Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Giuliani |
|
|
|
Darren |
Fenwick |
|
|
|
Michael |
Hurlbut |
|
|
|
Kristin |
McDonald |
|
|
|
Justin |
Fisher |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |